Latest news with #GCA
Time of India
4 days ago
- Sport
- Time of India
Shikha quits Goa cricket after 19 years, likely to join Baroda
The first Indian woman cricketer to score a half-century and take three wickets in the same ODI match, Shikha Pandey has captained Goa and South Zone teams in domestic tournaments Panaji: India allrounder Shikha Pandey has obtained a no objection certificate (NOC) from the Goa Cricket Association (GCA) to represent another state for the 2025-26 season. The first woman cricketer from Goa to play international cricket, Shikha has been the backbone of Goan cricket teams for close to two decades. She represented Goa for the first time in 2006 and has been among the top performers since then. 'Shikha sought an NOC to play outside Goa and we have given her permission,' GCA secretary Shamba Desai confirmed to TOI on Friday. 'It was her decision (to move) and we did not object.' Shikha was not available for a comment. Sources, however, said the seasoned allrounder is likely to join Baroda for this season, signalling a fresh chapter in her decorated domestic and international career. Last year, the 36-year-old represented Goa in domestic T20 tournament but was left out of the One-day squad along with six other prominent players like Shreya Parab, Vinavi Gurav, Sunanda Yetrekar, Tanaya Naik, Divya Naik and Metali Gawandar. 'We have to move on,' said Desai when asked whether Goa will miss out on Shikha's vast experience. Having made her debut for the national team in 2014, Shikha has since then represented the country in all three formats of the game — Test, One-day Internationals (ODIs), and T20 Internationals. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15+ Food That Clean Arteries (Most People Ignore) Undo She last represented India at the T20 World Cup 2023 in South Africa where she played three games and took three wickets. The first Indian woman cricketer to score a half-century and take three wickets in the same ODI match, Shikha has captained Goa and South Zone teams in domestic tournaments. In the Women's Premier League (WPL), she was central to Delhi Capitals finishing the competition as the runners-up twice in three years. Shikha has also played for Brisbane Heat women in the Women's Big Bash League (WBBL) and Trinbago Kolkata Knight Riders in the Women's Caribbean Premier League (WCPL). Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area. Get the latest lifestyle updates on Times of India, along with Raksha Bandhan wishes , messages and quotes !
Yahoo
7 days ago
- Health
- Yahoo
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) [1] AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19) in IV formulation [1] INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA® IV in the United States.[1] Earlier this year, the FDA approved AVTOZMA as a biosimilar to ACTEMRA in IV formulations for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19).[1] CRS is a potentially life-threatening condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. During a cytokine storm, the overactivated immune system can cause widespread inflammation and damage to healthy tissue and organs throughout the body with symptoms ranging from mild, flu-like symptoms to more severe complications such as low blood pressure, difficulty breathing, and multi-organ failure.[2] "We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas." In accordance with the patent settlement agreement with Genentech, the IV formulation of AVTOZMA is expected to be available in the U.S. on August 31, 2025. Celltrion holds a license to market the subcutaneous formulation in the U.S. commencing on the licensed launch date, which remains confidential. Notes to Editors: About AVTOZMA® (CT-P47, tocilizumab-anoh) AVTOZMA® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab. AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. INDICATION AVTOZMA® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA): Adult patients with GCA. Polyarticular Juvenile Idiopathic Arthritis (pJIA): Patients 2+ years-old with active pJIA. Systemic Juvenile Idiopathic Arthritis (sJIA): Patients 2+ years-old with active sJIA. Cytokine Release Syndrome (CRS): Adults and pediatric patients 2+ years-old with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. COVID-19: Hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS INFECTIONS AVTOZMA® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants. If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include: Active tuberculosis (TB) which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during treatment (except in COVID-19 patients) and treat latent infections before starting AVTOZMA. Invasive fungal infections: Such as candidiasis, aspergillosis, and pneumocystis, may present as disseminated rather than localized disease. Opportunistic infections, including bacterial, viral and other opportunistic pathogens. Monitor patients for signs of infection, including TB, during and after AVTOZMA Known hypersensitivity to tocilizumab Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled. Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management. Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop. Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts. Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant. Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity. Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders. Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended. Live Vaccines. Avoid concurrent use with AVTOZMA. Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions. For more information, see Full Prescribing Information. About Celltrion Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), STEQEYMA® (ustekinumab-stba), and AVTOZMA® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA® (infliximab-dyyb). For more information, please visit FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipates", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. Trademarks AVTOZMA® is a registered trademark of Celltrion is a registered trademark of Chugai Pharmaceutical Co., Ltd. References [1] AVTOZMA U.S. prescribing information (2025) [2] International Myeloma Foundation. What is Cytokine Release Syndrome (CRS)? Available at: For further information please contact:Andria Arenaaarena@ 516-578-0057 View original content to download multimedia: SOURCE Celltrion Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
23-07-2025
- Politics
- Time of India
Start work in two years, else will take back Pernem land: CM Sawant to Goa Cricket Association
Porvorim: Chief minister Pramod Sawant told the House on Wednesday that the Goa Cricket Association (GCA) is not serious about constructing a stand in Pernem for which 1.89 lakh sqm has been leased to it by govt. He said that eight years have passed, and the GCA hasn't even applied to the PWD for road access. In two more years, at the end of the ten-year lease, the land will be taken back by govt if construction does not begin, he said. Sawant said that last year, a show cause notice was issued to GCA, but the reply it provided was not satisfactory. Sawant said that the land is prime property today, with Manohar International Airport and the Ayush hospital in the vicinity. He also said that another govt department could put the land to better use. The CM also said that GCA has paid only Rs 9.4 crore to govt of the Rs 19 crore it was to pay. 'We issued a show cause notice to them last year, asked why should the lease not be terminated, and why the land should not be diverted for another project. They have not acquired the required permissions needed to create the ground,' he said. Pernem MLA Pravin Arlekar said that the land was given to GCA in 2018 and govt has not pressed for the project's progress. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Indonesia: New Container Houses (Prices May Surprise You) Container House | Search Ads Search Now Undo Arlekar said that the land should be taken back by govt and utilised by the state to create sports facilities for Pernem taluka instead. The CM, however, said that this is not an option. 'There are 153 grounds across Goa, but hardly 10-15 are being utilised. In Mencurem, I saw a ground with toilets and all facilities, but which is not being put to use. No other state has such facilities. There is one ground in every taluka. At this rate, in Goa, each panchayat will have a ground or I am afraid it will be two grounds per panchayat,' said Sawant. He said that GCA can identify land elsewhere if they cannot construct the project there for some reason. Leader of opposition Yuri Alemao said that govt has not added any penalty clause in the lease for GCA if it does not execute the project within the ten-year period. Mandrem MLA Jit Arolkar said that GCA has not even objected to high tension power lines going over the land.
![[Contribution] Kenya honors Ban Ki-moon: A beacon of environmental diplomacy, global leadership](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F07%2F22%2Fnews-p.v1.20250718.af04c21d56f94915bbe8fe13537e4dc7_T1.jpg&w=3840&q=100)
![[Contribution] Kenya honors Ban Ki-moon: A beacon of environmental diplomacy, global leadership](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
22-07-2025
- Politics
- Korea Herald
[Contribution] Kenya honors Ban Ki-moon: A beacon of environmental diplomacy, global leadership
At a historic ceremony at the State House in Nairobi on July 8, 2025, Kenya awarded its highest civilian honor, the Chief of the Order of the Golden Heart, to the 8th United Nations Secretary-General, Ban Ki-moon. The event highlighted Kenya's vital role in promoting sustainability and demonstrated the enduring influence of Ban's advocacy for climate action. The award, presented to him in Nairobi, recognized not only his extensive diplomatic achievements but also his profound and ongoing commitment to advancing multilateral cooperation in the fight against climate change. To put this into perspective, during his tenure at the United Nations, he championed landmark agreements, including the Paris Climate Accord. His relentless efforts to unite nations in pursuit of a greener, fairer world have left an indelible mark on global policy and inspired a new generation of leaders. Kenya's decision to recognize Ban's contributions serves as a testament to the country's leadership in environmental matters, reinforcing its reputation as a beacon of hope and innovation on the African continent. President William Ruto, in his tribute, described Ban as 'a bridge-builder and a champion of the world's most vulnerable,' praising his 'tireless advocacy and unwavering dedication to building a peaceful, just and sustainable world.' President Ruto noted that Ban's tenure as the eighth secretary-general of the United Nations was characterised by significant and transformative initiatives. His leadership played a crucial role in the adoption of the Paris Agreement on climate change, the establishment of UN Women to promote gender equality, and the introduction of the Sustainable Development Goals, which collectively aimed to address some of the most pressing global challenges. In his acceptance speech, Ban expressed deep gratitude, saying, 'It is humbling for me to receive such recognition in this beautiful country. Kenya means so much to me professionally and personally,' he said, noting that his daughter met her husband in Kenya and that his grandson spent his early years in Nairobi. This intimate and personal connection is not lost on Kenya, which has previously welcomed Ban Ki-moon in both private and official capacities. The award ceremony coincided with the groundbreaking of the dual headquarters of the Global Centre on Adaptation at the Kenya School of Government in Nairobi. The GCA is a leading international organization, currently headquartered in Rotterdam, Netherlands, housed in the world's largest floating office, with a focus on accelerating climate adaptation solutions. Its new African base will serve as a regional hub for policy dialogue, research and capacity-building. The establishment of dual headquarters symbolizes a bridge between the Global North and South in tackling climate challenges. The GCA's presence in Nairobi is an affirmation of Kenya's leadership in climate resilience and sustainable development. Ban's post-UN leadership is deeply rooted in climate resilience and sustainable development. As the President and Chair of the Global Green Growth Institute and co-founder of the GCA, he has continued to champion climate adaptation and green growth, particularly in vulnerable regions such as Africa. Kenya's connection with these two organizations is no coincidence. It shows a shared vision: that climate action should be inclusive, locally led and globally supported. When Ban was awarded in Nairobi, the only city in the global South hosting the United Nations headquarters, the United Nations Environment Program, which also houses the United Nations Office at Nairobi, offers a unique symbol of multilateral diplomacy that highlights Ban's career as a diplomat. It is worth noting that President William Ruto presented the award, as he is a leading voice in global climate leadership, serving as the chair of the Committee of African Heads of State and Government on Climate Change. Kenya's decision to honor Ban is not only symbolic but also a strategic affirmation of the country's dedication to environmental diplomacy. Ban's remarks during the ceremony captured the urgency and hope that characterize the climate movement: 'Climate change is the greatest collective challenge we face as a human family. But it is also our greatest opportunity for common progress towards a sustainable future.' He added, 'The longer we delay, the more we will pay.' These words resonate deeply in Kenya, where communities are already grappling with the effects of droughts, floods and biodiversity loss. Yet, through innovation, policy reform and international cooperation, Kenya is forging a path forward that prioritizes people, the planet and prosperity. The conferment of the Chief of the Order of the Golden Heart on Ban is more than a ceremonial gesture. It is a declaration of Kenya's values: solidarity, sustainability and global citizenship. It honors a legacy of leadership that has shaped the world and signals Kenya's readiness to lead in the next chapter of international climate action. As Ban eloquently stated, "That this century is Africa's century and Kenya is not just a leader in Africa, it is a global example of how nations can rise to meet the challenges of our time with courage, innovation and unity.' In celebrating Ban, Kenya celebrates the power of diplomacy, the promise of green growth and the potential of a continent poised to shape the future. sanjaykumar@
Barnama
21-07-2025
- Business
- Barnama
Talentbank Unveils GCA 2025 Winners, Highlighting Malaysia's Most Preferred Employers
KUALA LUMPUR, July 21 (Bernama) -- Talentbank, Malaysia's leading authority on graduate employability, has announced the winners of the Graduates' Choice Award (GCA) 2025, reaffirming the influence of student voices in shaping the nation's top employment brands. Touted as Malaysia's largest student-driven employer branding award, the GCA recorded a remarkable 597,036 votes from students across more than 100 universities, setting a new benchmark for graduate engagement and transparency. Now in its eighth year, the award continues to reflect the authentic preferences of Malaysia's future workforce. The GCA honours employers that stand out in key areas such as career development, leadership opportunities, employee well-being and workplace culture. Winners for 2025 span a wide range of sectors, from multinational corporations and homegrown enterprises to fashion labels, tech giants, FMCG leaders, healthcare providers and digital platforms. Talentbank founder and chief executive officer Ben Ho said the award is a key benchmark for employers looking to align more closely with graduate expectations. 'The Graduates' Choice Award represents the collective voice of Malaysia's emerging talent. Employers that pay attention to these insights gain a competitive edge, understanding precisely what young professionals seek in their career journeys,' he said in a statement. Findings from the GCA 2025 survey reveal a clear shift in priorities among Gen Z graduates. While competitive pay still matters, it is no longer the sole driver of career choices. Instead, today's graduates are seeking holistic career experiences, placing greater emphasis on meaningful work, job security, mentorship, growth opportunities, flexibility, and mental well-being, the statement read.
